Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 202: Sotorasib plus platinum doublet vs pembrolizumab plus platinum doublet in first-line KRAS G12C, PD-L1–negative advanced nonsquamous NSCLC
jRCT2061230078Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sotorasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Amgen. Primary endpoints: Progression-free survival (PFS) and Overall survival (OS). Started Nov 2023; status: recruiting.
02
Drugs
sotorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2061230078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230078.